Novanta (NASDAQ:NOVT – Get Free Report) updated its fourth quarter earnings guidance on Tuesday. The company provided earnings per share (EPS) guidance of $0.70-0.74 for the period, compared to the consensus estimate of $0.97. The company issued revenue guidance of $237-242 million, compared to the consensus revenue estimate of $263.99 million. Novanta also updated its FY 2024 guidance to 3.020-3.060 EPS.
Novanta Stock Performance
NOVT traded down $0.42 during trading on Thursday, hitting $181.52. The stock had a trading volume of 169,551 shares, compared to its average volume of 140,863. The company has a debt-to-equity ratio of 0.68, a current ratio of 2.77 and a quick ratio of 1.73. The firm has a market cap of $6.52 billion, a price-to-earnings ratio of 104.92 and a beta of 1.29. The company has a 50 day moving average price of $174.22 and a 200-day moving average price of $169.85. Novanta has a one year low of $119.64 and a one year high of $187.12.
Novanta (NASDAQ:NOVT – Get Free Report) last announced its earnings results on Tuesday, November 5th. The technology company reported $0.85 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.85. Novanta had a net margin of 6.91% and a return on equity of 15.77%. The company had revenue of $244.40 million during the quarter, compared to analysts’ expectations of $242.33 million. During the same quarter in the previous year, the business posted $0.85 earnings per share. Novanta’s quarterly revenue was up 10.3% on a year-over-year basis. As a group, research analysts predict that Novanta will post 3.3 EPS for the current year.
Analyst Upgrades and Downgrades
Check Out Our Latest Stock Report on NOVT
Insider Transactions at Novanta
In related news, CFO Robert Buckley sold 3,660 shares of the firm’s stock in a transaction dated Tuesday, October 1st. The stock was sold at an average price of $174.01, for a total value of $636,876.60. Following the sale, the chief financial officer now directly owns 120,419 shares of the company’s stock, valued at $20,954,110.19. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. In the last quarter, insiders sold 9,150 shares of company stock valued at $1,608,936. Corporate insiders own 1.20% of the company’s stock.
Novanta Company Profile
Novanta Inc, together with its subsidiaries, provides precision medicine and manufacturing, medical solutions, and robotics and automation solutions in the United States and internationally. The company operates through three segments: Precision Medicine and Manufacturing, Medical Solutions, and Robotics and Automation.
Read More
- Five stocks we like better than Novanta
- What does consumer price index measure?
- Gilead’s Stock Surge: What’s Fueling the Momentum?
- Best of the list of Dividend Aristocrats: Build wealth with the aristocrat index
- Breakout Alert: Qualcomm Just Hit The Rally Button
- Learn Technical Analysis Skills to Master the Stock Market
- Mercado Libre Shares Go on Sale: Is Now the Time to Buy?
Receive News & Ratings for Novanta Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novanta and related companies with MarketBeat.com's FREE daily email newsletter.